Vascular disease has become the number one killer of endangering human health. However, studies from various countries show that early detection and intervention treatment of vascular diseases are important means to effectively stop the occurrence of end point. In recent years, academia attaches great importance to the prevention of related diseases. In this year's "Eleventh Five-year" scientific and technological project, the support for prevention of cardiovascular diseases and other diseases is also very strong. With the revision of the international academic guidelines on the treatment of hypertension, the diagnosis, treatment and prevention of hypertension and other cardiovascular diseases in the world will be improved.

     Of particular note was the 17th European Hypertension Conference held in Milan, Italy, June 15-19, 2007, when delegates decided to include central aortic blood pressure in the blood pressure indicator to be measured for the management of hypertension, Hypertension treatment guidelines for the first time in four years. 2006 Anglo-Scandinavian Cardiac End-point Trial - Branching Study of the Antihypertensive Section Results of the ASCOT-CAFé study were published and formally published. This study, for the first time in many prospective clinical trials in patients with large sample size repeated determination of central aortic pressure, confirmed that the parameters of central aortic pressure and cardiovascular disease end point events are closely linked.

     At the related press conference held during the 18th Great Wall International Cardiology Symposium, the news on "Central Aorta Blood Pressure Measurement Becomes a New Indicator of Hypertension Management" was released, arousing widespread concern in the industry.

     Reporters learned from the conference, the use of lower central aortic blood pressure therapy can make antihypertensive treatment more effective, so that doctors can better diagnose, treat and prevent hypertension, myocardial infarction, cardiac hypertrophy, arteriosclerosis and other heart Vascular disease. Central arterial pressure, reflex enhancement index (AI) is not only closely related to the end point of cardiovascular and cerebrovascular events. Its usability is also reflected in the following aspects: (1) dialysis patients and cardiac left ventricular weight (LVMI) related. For patients with elevated cardiac load and left ventricular hypertrophy, patients can be presumed to have high AI. (2) AI in patients with advanced renal insufficiency increased, there are independent factors of early warning of death. A 10% increase in AI has a 1.51-fold increase in all-cause mortality and a 1.48-fold increase in cardiovascular disease mortality. (3) Evaluation of the effect of AI on peripheral vasodilators and the like is a useful indicator.

     In the past to accurately measure the central aortic blood pressure is not easy, the typical method is invasive, that is, a catheter inserted into the heart. Invasive detection of invasive characteristics of the decision that it can not be widely used in early detection of arterial lesions. Therefore, we must use a non-invasive non-invasive inspection method. Omron Healthcare launched a radial pulse wave monitor in Japan in 2005 that makes it possible to assess central aortic blood pressure easily and noninvasively. There is a close correspondence between the pressure of the peripheral muscular aorta (radial artery) and the pressure of the elastic aorta (aorta), so as to establish the mathematical transformation between the two. Through invasive testing, the ascending aortic blood pressure obtained from the radial conversion of the radial artery has been compared with the actual measurement, and many studies have demonstrated the reliability and accuracy of mathematical conversion even in patients with frequent premature beats or atrial fibrillation in this way.

     Reporters learned through Omron-Colin executives that they studied a system for measuring central arterial pressure by using advanced multi-point pressure sensing technology to have a 40-lead pressure-sensing probe fixed at the radial artery of the wrist, The probe automatically finds the strongest radial artery pulse point, collecting pressure wave signal, calculate the central arterial pressure and AI value. The instrument was launched in the United States in 2006 and is being rolled out in Europe, China, Taiwan and South Korea at the same time. The instrument for the evaluation of the efficacy of antihypertensive drugs, antihypertensive treatment to optimize the program and clinical early diagnosis and screening of atherosclerosis great help. OMRON cooperation with medical institutions is also further underway.